Development of Propensity Score Model.

<p><b>Table A.</b> Deviations from protocol. <b>Table B.</b> List of variables considered and included in propensity score model for balancing characteristics between exposure groups. <b>Table C.</b> Baseline characteristics and standardised differences of trial-eligible patients after applying trial criteria included in inverse-probability—weighted analysis before and after weighting for the reference trial emulation. <b>Table D.</b> Baseline characteristics and standardised differences of trial-eligible Black patients after applying trial criteria included in inverse-probability—weighted analysis before and after weighting for extending analysis to underrepresented groups. <b>Table E.</b> Baseline characteristics and standardised differences of trial-eligible South Asian patients after applying trial criteria included in inverse-probability—weighted analysis before and after weighting for extending analysis to underrepresented groups. <b>Table F.</b> Baseline characteristics and standardised differences of trial-eligible White patients after applying trial criteria included in inverse-probability—weighted analysis before and after weighting for extending analysis to underrepresented groups. <b>Table G.</b> Number of events for the primary outcome, its components, main secondary outcome, and death from any cause for ARB vs. ACEi using an inverse-probability—weighted analysis of trial-eligible patients in CPRD Aurum after emulation and benchmarking findings against the reference trial (ONTARGET). <b>Table H.</b> Comparative effectiveness of ARB vs. ACEi for the primary and secondary outcomes overall and by ethnicity with a test for multiplicative heterogeneity using an inverse-probability—weighted analysis of trial-eligible patients in CPRD Aurum with an on-treatment approach. <b>Table I.</b> Comparative effectiveness of ARB vs. ACEi for the primary and secondary outcomes overall and by ethnicity using an inverse-probability—weighted analysis of trial-eligible patients in CPRD Aurum with after multiple imputation of missing values. <b>Table J.</b> Table of trial diagnoses (inclusion criteria) and interpretation in CPRD. <b>Table K.</b> Table of trial exclusion criteria and interpretation in CPRD. <b>Fig A.</b> Steps to define analysis cohort. <b>Fig B.</b> Directed acyclic graph to identify confounders for propensity score model. <b>Fig C.</b> Histogram of propensity score distribution after trimming extreme weights for patients of Black ethnicity. <b>Fig D.</b> Histogram of propensity score distribution after trimming extreme weights for patients of South Asian ethnicity. <b>Fig E.</b> Histogram of propensity score distribution after trimming extreme weights for patients of White ethnicity. <b>Fig F.</b> Proportion of ARB and ACE inhibitor prescriptions prescribed each year out of total number prescribed within each ethnic group. <b>Fig G.</b> Forest plot of sensitivity analysis for extending analysis to underrepresented groups using an inverse-probability—weighted analysis for ARB vs. ACEi use for primary composite outcome.</p> <p>(PDF)</p>